Enanta Pharmaceuticals (ENTA) shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.6% loss over the past four weeks. Last week, the company announced positive top-line data from a phase IIa human challenge study evaluating its pipeline candidate, EDP-323, in healthy adults infected with respiratory syncytial virus. The study met primary and secondary endpoints by de ...